M5717

Merck KGaA

Product vision
  • Part of single-exposure treatment of uncomplicated malaria

  • Potential for prophylaxis

MoA
  • P. falciparum EF2 inhibitor novel mechanism of action

Key features
  • Comparable activity across all stages of the malaria parasite lifecycle 

  • Predicted dose to give coverage above Minimal Parasiticidal Concentration for >8 days is 500mg 

  • Excellent transmission-blocking activity in a Standard Membrane Feeding Assay

Status
  • First-in-human study and volunteer infection study ongoing

Next milestone
  • Complete Phase I studies and move into patients with combination product

Previously
  • Names DDD107498; DDD498, MMV121; Discovery collaboration with the University of Dundee Drug Discovery Unit
MMV Project Director
  • Dr Cristina Donini